[1] Maxova H, Herget J, Vizek M. Lung mast cells and hypoxic pulmonary hypertension［J］. Physiol Res, 2012, 61 (1):1-11.
[2] Humbert M, Montani D, Evgenov OV, et al. Definition and classification of pulmonary hypertension［J］. Handb Exp Pharmacol, 2013, 218:3-29.
[3] Poor HD, Girgis R, Studer SM. World Health Organization Group Ⅲ pulmonary hypertension［J］. Prog Cardiovasc Dis, 2012, 55 (2):119-127.
[4] Hoffmann J, Yin J, Kukucka M, et al. Mast cells promote lung vascular remodelling in pulmonary hypertension［J］. Eur Respir J, 2011, 37 (6):1400-1410.
[5] Karar J, Cerniglia GJ, Lindsten T, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1 alpha expression by blocking protein translation and increases cell death under hypoxia［J］. Cancer Biol Ther, 2012, 13 (11):1102-1111.
[6] Fang X, Li K, Tao X, et al. Effects of phosphoinositide 3-kinase on protease-induced acute and chronic lung inflammation, remodeling, and emphysema in rats［J］. Chest, 2013, 143 (4):1025-1035.
[7] Blatt K, Herrmann H, Mirkina I, et al. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils［J］. PLoS One, 2012, 7 (1):e29925.
[8] Council NR. Guide for the care and use of laboratory animals［M］.8th Ed. Washington DC:National Academies Press,2011:11-151.
[9] Tucker A, Mcmurtry IF, Alexander AF, et al. Lung mast cell density and distribution in chronically hypoxic animals［J］. J Appl Physiol Respir Environ Exerc Physiol, 1977, 42 (2):174-178.
[10] Bartelds B, Van Loon RL, Mohaupt S, et al. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension［J］. Chest, 2012, 141 (3):651-660.
[11] Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity［J］. Mol Cancer Ther, 2008, 7 (7):1851-1863.
[12] Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia［J］. Clin Chest Med, 2013, 34 (4):695-705.
[13] Jin H, Wang Y, Zhou L, et al. Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells［J］. J Pineal Res, 2014, 57 (4):442-450.
[14] Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms［J］. Circ Res, 2006, 99 (7):675-691.